Table 1: Open in new tab Patient...

Table 1:

Patient characteristics

Variables	Age	Gender	Smoking history (years)	FEV1 (%)	FVC (%)	VC (%)	Histology	Neoadjuvant chemotherapy	Clinical stage
Case 1	55	Male	40	60	75	87	SC	0	T3N0M0
Case 2	55	Male	48	74	77	99	SC	0	T3N0M0
Case 3	60	Male	38	72	80	80	SC	0	T3N0M0
Case 4	61	Female	0	72	88	88	CR	6 EC	T4N0M0
Case 5	69	Male	50	64	100	123	SC	0	T3N0M0
Case 6	65	Male	50	48	44	64	SC	4 EP	T3N0M0
Case 7	57	Male	42	78	66	92	SC	0	T3N0M0
Case 8	57	Male	40	88	75	86	SC	3 EP	T2N2M0
Case 9	61	Male	40	54	50	51	SC	4 EP	T4N0M0
Case 10	60	Male	40	79	61	79	SC	3 EP	T4N1M0
Case 11	55	Male	40	80	84	84	SC	0	T4N0M0
Case 12	59	Male	40	48	66	75	ADC	0	T2N0M0
Case 13	54	Male	35	62	86	88	SC	4 GC	T4N2M0
Case 14	57	Male	38	88	78	101	SC	0	T3N0M0
Case 15	62	Male	40	50	70	86	ADC	3 GC	T3N2M0
Case 16	57	Male	45	88	78	101	SC	0	T3N0M0

Variables	Age	Gender	Smoking history (years)	FEV1 (%)	FVC (%)	VC (%)	Histology	Neoadjuvant chemotherapy	Clinical stage
Case 1	55	Male	40	60	75	87	SC	0	T3N0M0
Case 2	55	Male	48	74	77	99	SC	0	T3N0M0
Case 3	60	Male	38	72	80	80	SC	0	T3N0M0
Case 4	61	Female	0	72	88	88	CR	6 EC	T4N0M0
Case 5	69	Male	50	64	100	123	SC	0	T3N0M0
Case 6	65	Male	50	48	44	64	SC	4 EP	T3N0M0
Case 7	57	Male	42	78	66	92	SC	0	T3N0M0
Case 8	57	Male	40	88	75	86	SC	3 EP	T2N2M0
Case 9	61	Male	40	54	50	51	SC	4 EP	T4N0M0
Case 10	60	Male	40	79	61	79	SC	3 EP	T4N1M0
Case 11	55	Male	40	80	84	84	SC	0	T4N0M0
Case 12	59	Male	40	48	66	75	ADC	0	T2N0M0
Case 13	54	Male	35	62	86	88	SC	4 GC	T4N2M0
Case 14	57	Male	38	88	78	101	SC	0	T3N0M0
Case 15	62	Male	40	50	70	86	ADC	3 GC	T3N2M0
Case 16	57	Male	45	88	78	101	SC	0	T3N0M0

ADC: adenocarcinoma; CR: carcinoid tumour; EC: etoposide + carboplatin; EP: etoposide + paclitaxel; FEV₁: forced expiratory volume in 1 second; FVC: forced vital capacity; GC: gemzar + cisplatin; SC: squamous cell carcinoma; VC: vital capacity.

This Feature Is Available To Subscribers Only